Northern Institute for Cancer Research

Staff Profile

Huw Thomas

Senior Research Associate

Background

Qualifications

BSc (hons) Pharmacology 1991
MPhil 1999

Previous Positions

Research Technician 1993-1996
Junior Research associate 1996-2000

Memberships

BACR
PAMM

Research

Research Interests

Pharmacology of novel drugs to treat cancer
Pharmacokinetics

Other Expertise

Analysis of drugs in biological material

Current Work

Evaluation of, novel drugs to inhibit DNA repair-mediated resistance to anticancer therapy, CDK inhibitors and novel nucleoside transport inhibitors to enhance antifolate efficacy.

Postgraduate Supervision

MRes student supervision 2004

Funding

Preclinical and pharmacodynamic studies with Novel DNA-PK inhibitors. N.J. Curtin (PI, 40%) A.H. Calvert (5%), BW Durkacz (10%), BT Golding (5%), RJ Griffin (5%), IR Hardcastle (5%), D.R. Newell (20%), H. Thomas (10%). KuDos Pharmaceuticals 06/02-05/06 £355,171

Preclinical evaluation of DNA-PK and ATM inhibitors. N.J. Curtin (PI, 40%) A.H. Calvert (5%), BW Durkacz (10%), BT Golding (5%), RJ Griffin (5%), IR Hardcastle (5%), D.R. Newell (20%), H. Thomas (10%). KuDos Pharmaceuticals 01/03-12/06 £413,088

Preclinical Evaluation of AT5438 D.R. Newell (PI = 50%) N.J. Curtin (25%), H. Thomas (25%). Astex Technology Ltd 05/03-05/04 £15,253

Publications